Acute Myeloid Leukemia | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Introduction VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome
is a recently described, late-onset, acquired autoinflammatory disorder caused by mutations …

An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …

In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …

Purpose Age has long been used as a major factor for assessing suitability for allogeneic
hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was …

Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative
conditioning regimen (MAC) before allogeneic transplantation in patients with …

Background Acute myeloid leukemia is the second most common leukemia among United
States adults with a median age of 69 years. We investigated recent clinical practices related …